ICER Analyses Increasingly Guide US Price Negotiations, Payers Report
Nearly 65% of respondents reported ICER cost effectiveness reviews are 'likely' or 'extremely likely' to function as a benchmark in price negotiations with manufacturers, according to a recent survey.
You may also be interested in...
Drug makers have sought a larger role for RWE in ICER's review process; proposed update also includes process to re-evaluate cost-effectiveness evidence after one year.
Comments to HHS on the Trump Administration’s US drug pricing blueprint recommend that cost effectiveness analyses by the Institute for Clinical and Economic Review could help promote value-based pricing.
Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.